
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a clinical-stage TechBio company with a promising AI platform that harnesses the power of artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. In a collaboration with Duke University, Evaxion presented a personalized vaccine strategy utilizing their AI-Immunology platform to identify both tumor neoantigens and endogenous retroviral-derived antigens for glioblastoma. With a Buy rating and a $16.00 price target, the company shows potential for significant growth in the future. However, risks to the outlook include potential issues with partnerships, technology, clinical trials, regulatory approvals, commercialization, legal and intellectual property, competition, and dilution.
Bears say
Evaxion is undergoing a strategic pivot into autoimmune disease (AID) therapies, aiming to optimize their AI-Immunology platform and select 2-3 lead indications for launch in 2026. However, without specific indications disclosed, it is unclear how marketable these therapies will be and the potential impact on Evaxion's licensing strategy. This lack of clarity, coupled with the uncertainty of niche versus higher prevalence AID indications, leads to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares